POU2F3 and small cell lung carcinoma: SCLC-Ib, marked by immunosuppressive characteristics and high genomic instability, shows that patients with high POU2F3 expression respond better to immunotherapy.[28,45] These findings provide a clinically relevant method to distinguish SCLC patients more likely to benefit from immunotherapies.